Safety of direct oral anticoagulants: insights from postmarketing studies

被引：5

作者：

Villines, Todd C. ^{[1
]}

Peacock, W. Frank ^{[2
]}

机构：

[1] Walter Reed Natl Mil Med Ctr, Serv Cardiol, Dept Med, Bethesda, MD USA

[2] Baylor Coll Med, Dept Emergency, Med, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF EMERGENCY MEDICINE | 2016年 / 34卷 / 11期

关键词：

NONVALVULAR ATRIAL-FIBRILLATION; ANTITHROMBOTIC TREATMENT; DABIGATRAN; WARFARIN; REGISTRY; APIXABAN; STROKE; RISK; CARE; RIVAROXABAN;

D O I：

10.1016/j.ajem.2016.09.047

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Direct oral anticoagulants (DOACs) have been marketed in the United States since 2010. While numerous large-scale prospective phase 3 outcomes studies have documented the effectiveness of DOACs for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, the primary safety concern with all of these drugs-as it is with the more established oral anticoagulant warfarin-is the risk of major bleeding. Postmarketing surveillance studies (PMSS) provide the opportunity to evaluate the safety of these recently approved drugs across a spectrum of patients that may be broader than those included in randomized controlled trials. This review will summarize the safety findings of numerous recently performed, large-scale PMSS evaluations, and consider the currently available evidence regarding the risks for bleeding in patients treated with DOACs, in order to give providers and patients additional evidence regarding the safety of DOACs. (C) 2016 The Authors. Published by Elsevier Inc.

引用

页码：9 / 13

页数：5

共 30 条

[1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Ageno, Walter ;

Gallus, Alexander S. ;

Wittkowsky, Ann ;

Crowther, Mark ;

Hylek, Elaine M. ;

Palareti, Gualtiero .

CHEST, 2012, 141 (02) :E44S-E88S

[2] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[3] An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants [J].

Deitelzweig, Steve ;

Bruno, Amanda ;

Trocio, Jeffrey ;

Tate, Natalie ;

Gupta, Kiran ;

Lin, Jay ;

Lingohr-Smith, Melissa .

CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (03) :573-582

[4] Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems [J].

Glasser, Stephen P. ;

Salas, Maribel ;

Delzell, Elizabeth .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09) :1074-1086

[5] Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation [J].

Graham, David J. ;

Reichman, Marsha E. ;

Wernecke, Michael ;

Zhang, Rongmei ;

Southworth, Mary Ross ;

Levenson, Mark ;

Sheu, Ting-Chang ;

Mott, Katrina ;

Goulding, Margie R. ;

Houstoun, Monika ;

MaCurdy, Thomas E. ;

Worrall, Chris ;

Kelman, Jeffrey A. .

CIRCULATION, 2015, 131 (02) :157-164

[6] Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].

Granger, Christopher B. ;

Alexander, John H. ;

McMurray, John J. V. ;

Lopes, Renato D. ;

Hylek, Elaine M. ;

Hanna, Michael ;

Al-Khalidi, Hussein R. ;

Ansell, Jack ;

Atar, Dan ;

Avezum, Alvaro ;

Cecilia Bahit, M. ;

Diaz, Rafael ;

Easton, J. Donald ;

Ezekowitz, Justin A. ;

Flaker, Greg ;

Garcia, David ;

Geraldes, Margarida ;

Gersh, Bernard J. ;

Golitsyn, Sergey ;

Goto, Shinya ;

Hermosillo, Antonio G. ;

Hohnloser, Stefan H. ;

Horowitz, John ;

Mohan, Puneet ;

Jansky, Petr ;

Lewis, Basil S. ;

Luis Lopez-Sendon, Jose ;

Pais, Prem ;

Parkhomenko, Alexander ;

Verheugt, Freek W. A. ;

Zhu, Jun ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992

[7] Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II [J].

Huisman, Menno V. ;

Rothman, Kenneth J. ;

Paquette, Miney ;

Teutsch, Christine ;

Diener, Hans Christoph ;

Dubner, Sergio J. ;

Halperin, Jonathan L. ;

Ma, Changsheng ;

Zint, Kristina ;

Elsaesser, Amelie ;

Bartels, Dorothee B. ;

Lip, Gregory Y. H. .

AMERICAN JOURNAL OF MEDICINE, 2015, 128 (12) :1306-+

[8] International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) [J].

Kakkar, Ajay K. ;

Mueller, Iris ;

Bassand, Jean-Pierre ;

Fitzmaurice, David A. ;

Goldhaber, Samuel Z. ;

Goto, Shinya ;

Haas, Sylvia ;

Hacke, Werner ;

Lip, Gregory Y. H. ;

Mantovani, Lorenzo G. ;

Verheugt, Freek W. A. ;

Jamal, Waheed ;

Misselwitz, Frank ;

Rushton-Smith, Sophie ;

Turpie, Alexander G. G. .

AMERICAN HEART JOURNAL, 2012, 163 (01) :13-U31

[9] Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10 [J].

Kokotailo, RA ;

Hill, MD .

STROKE, 2005, 36 (08) :1776-1781

[10] Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation [J].

Larsen, Torben Bjerregaard ;

Gorst-Rasmussen, Anders ;

Rasmussen, Lars Hvilsted ;

Skjoth, Flemming ;

Rosenzweig, Mary ;

Lip, Gregory Y. H. .

AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07) :650-+

← 1 2 3 →